| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/31/2002 | WO2002007759A2 Clostridial toxin derivatives and methods for treating pain |
| 01/31/2002 | WO2002007758A2 Method for induced lactation |
| 01/31/2002 | WO2002007757A2 Prevention and treatment of sexual arousal disorders |
| 01/31/2002 | WO2002007756A1 MuO-CONOPEPTIDES AND THEIR USE AS LOCAL ANESTHETICS |
| 01/31/2002 | WO2002007755A1 Lrp-mediated modulation of neuronal calcium influx via nmda receptors, and uses thereof |
| 01/31/2002 | WO2002007754A2 New use |
| 01/31/2002 | WO2002007753A2 Method for treating unstable angina pectoris |
| 01/31/2002 | WO2002007752A2 Red blood cell as vehicle for agent-membrane translocation sequence conjugate |
| 01/31/2002 | WO2002007751A1 Identification and isolation of novel polypeptides having pdz domains and methods of using same |
| 01/31/2002 | WO2002007750A1 Alpha-conotoxin peptides |
| 01/31/2002 | WO2002007748A2 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor |
| 01/31/2002 | WO2002007747A1 Methods of modulating fibrosis |
| 01/31/2002 | WO2002007740A2 Snake toxin and use thereof as a pharmaceutical |
| 01/31/2002 | WO2002007730A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | WO2002007720A1 Compounds having mif antagonist activity |
| 01/31/2002 | WO2002007707A2 Linkage of agents using microparticles |
| 01/31/2002 | WO2002007678A2 Mu-conopeptides |
| 01/31/2002 | WO2002007676A2 Compounds having affinity for the granulocyte-colony stimulating factor receptor (g-csfr) |
| 01/31/2002 | WO2002007675A2 Omega-conopeptides |
| 01/31/2002 | WO2002007646A2 Artificial vascular grafts, and methods of producing and using same |
| 01/31/2002 | WO2002007514A2 Glycosylated vegf-b and method for increasing the amount of soluble vegf-b |
| 01/31/2002 | WO2001083693A8 Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses |
| 01/31/2002 | WO2001083562A3 Hybrid protein and vector encoding the same for inhibition of angiogenesis |
| 01/31/2002 | WO2001080873A3 Thrombopoietin receptor modulating peptide |
| 01/31/2002 | WO2001079461A3 Polypeptides having haloperoxidase activity |
| 01/31/2002 | WO2001074381A3 Calpain inhibitors in cancer treatment |
| 01/31/2002 | WO2001068868A3 Alpha(iii) subunit of prolyl 4-hydroxylase |
| 01/31/2002 | WO2001068146A3 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| 01/31/2002 | WO2001068120A3 Uses of bombesin receptor 3 |
| 01/31/2002 | WO2001064870A3 Mutated cyclin g1 protein |
| 01/31/2002 | WO2001062940A3 New phosphodiesterase type 7b |
| 01/31/2002 | WO2001062785A3 Protein and gene and their use for diagnosis and treatment of schizophrenia |
| 01/31/2002 | WO2001062784A3 Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer |
| 01/31/2002 | WO2001062775A3 Novel antiarrhythmic peptides |
| 01/31/2002 | WO2001062280A3 Lipase-containing composition and methods of use thereof |
| 01/31/2002 | WO2001061017A3 Modified cytokines for use in cancer therapy |
| 01/31/2002 | WO2001060416A3 Matrix metalloproteinase inhibitors as targeting components in diagnostic agents |
| 01/31/2002 | WO2001057075A3 Virulence genes, proteins, and their use |
| 01/31/2002 | WO2001057065A3 Combinatorial protein domains |
| 01/31/2002 | WO2001054472A3 Nucleic acids, proteins, and antibodies |
| 01/31/2002 | WO2001053322A3 Aerothricin analogs, their preparation and use |
| 01/31/2002 | WO2001052894A3 Nasally administrable cyclic peptide compositions |
| 01/31/2002 | WO2001049716A3 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| 01/31/2002 | WO2001048485A3 Selecting library members capable of binding to epitopes |
| 01/31/2002 | WO2001044284A3 Chimeric natriuretic peptides |
| 01/31/2002 | WO2001042457A3 Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s prnas and their uses |
| 01/31/2002 | WO2001040473A3 Pseudomonas aeruginosa antigens |
| 01/31/2002 | WO2001040259A3 Monkey orexin 1 receptor |
| 01/31/2002 | WO2001039788A3 Methods for targeting cells that express fibroblast growth receptor-3 or-2 |
| 01/31/2002 | WO2001038503A3 Novel human protein kinases and protein kinase-like enzymes |
| 01/31/2002 | WO2001036605A3 2786, a human aminopeptidase |
| 01/31/2002 | WO2001034801A3 Recombinant gelatin in vaccines |
| 01/31/2002 | WO2001034177A3 Method of treating a viral infection using antagonists of macrophage colony stimulating factor |
| 01/31/2002 | WO2001031343A3 Diagnosis and therapy of cancer using sgp28-related molecules |
| 01/31/2002 | WO2001029085A3 Cdt6 can inhibit angiogenesis and tumor growth, and can induce or enhance the formation of structures containing collagen v |
| 01/31/2002 | WO2001021836A3 Molecules for diagnostics and therapeutics |
| 01/31/2002 | WO2001008634A3 Polynucleotide encoding a human serine protease |
| 01/31/2002 | WO2000072869A9 Methods for producing 5'-nucleic acid-protein conjugates |
| 01/31/2002 | WO2000062794A9 A non-immunosuppressive process for inducing acceptance of incompatible transplants |
| 01/31/2002 | WO2000059941A9 Purposeful movement of human migratory cells away from an agent source |
| 01/31/2002 | WO2000047219A3 Methods and reagents for treating glucose metabolic disorders |
| 01/31/2002 | WO1998021343A8 Genes encoding telomerase proteins |
| 01/31/2002 | US20020013953 Transgenic mammal; for use as model in evaluating lysosomal storage defects |
| 01/31/2002 | US20020013458 Enzymatic nucleic acid treatment of disases or conditions related to hepatitis c virus infection |
| 01/31/2002 | US20020013456 Cortistatin: neuropeptides, compositions and methods |
| 01/31/2002 | US20020013452 Nucleotide sequences coding cytokine; for use in cancer treatment |
| 01/31/2002 | US20020013357 Valdecoxib compositions |
| 01/31/2002 | US20020013320 Use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease |
| 01/31/2002 | US20020013315 For therapy Alzheimer's disease |
| 01/31/2002 | US20020013288 Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
| 01/31/2002 | US20020013285 Nucleosome-based anti-tumor compositions |
| 01/31/2002 | US20020013284 Administering Product R, a peptide-nucleic acid preparation, to patients having rheumatoid arthritis; analgesics; antiinflammatory, -swelling, -arthritic agents |
| 01/31/2002 | US20020013279 Hematopoietic stimulation |
| 01/31/2002 | US20020013278 Using an interleukin-1 beta converting enzyme inhibitor pro-drug to treat apoptosis-, interferon-gamma inducing factor or interferon-gamma inducing diseases; antiinflammatory and -proliferative agents; autoimmune/degenerative disesesdiseases |
| 01/31/2002 | US20020013277 Composition and methods to improve neural outcome |
| 01/31/2002 | US20020013276 Investigational compounds |
| 01/31/2002 | US20020013274 Administering a covalently reactive antigen analog (CRAA) having an an epitope recognized irreversibly bound by catalytic antibody; autoimmune disease; a lymphoproliferative disorder; anticarcinogenic, -tumor, -inflammatory agents |
| 01/31/2002 | US20020013273 Method for producing sustained-release formulations |
| 01/31/2002 | US20020013272 Comprising a cyclosporin in a carrier medium of a fatty acid triglyceride and a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester; biavailability; side-effect reductions |
| 01/31/2002 | US20020013269 Human insulin analogues |
| 01/31/2002 | US20020013268 Synergistic effect of a sulfonylurea and/or non-sulfonylurea Kchannel blocker, and a phosphodiesterase 3 type inhibitor |
| 01/31/2002 | US20020013267 Inhibition of neonatal hyperbilirubinemia in breast fed infants |
| 01/31/2002 | US20020013266 Polymer stabilized neuropeptides |
| 01/31/2002 | US20020013265 Administering Hepatocyte Growth Factor to decrease mucosal damage of the small intestine, treat histologic lesions, increase absorption, reduce gene expression inflammatory mediators; chronic ulcerative colitis; Crohn's disease |
| 01/31/2002 | US20020013264 Glycosylaminoglycan (GAG) chains chemically modified with a carbodiimide such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide |
| 01/31/2002 | US20020013263 Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| 01/31/2002 | US20020013262 Method of inhibiting metastatic dissemination using desmopressin |
| 01/31/2002 | US20020013261 Contacting a localized area of tissue with the polymer; treating ischemia |
| 01/31/2002 | US20020013259 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders |
| 01/31/2002 | US20020013258 Novel stem cell factor formulations and methods |
| 01/31/2002 | US20020012997 Transducing cell; incubate cells with nucleotide sequences, insert cells into mammals, monitor mammals for phenotypic adjustment |
| 01/31/2002 | US20020012989 Genetically engineered nucleotide sequences coding preferential proteins for use in treatment of viral disease |
| 01/31/2002 | US20020012983 Novel subunits of nadh dehydrogenase |
| 01/31/2002 | US20020012967 Insulin homolog polypeptide zins4 |
| 01/31/2002 | US20020012966 18 Human secreted proteins |
| 01/31/2002 | US20020012965 Nucleotide sequences coding prfeerential polypeptides for use in the diagnosis and treatment of brain disorders and injury |
| 01/31/2002 | US20020012964 Polypeptide for use in the diagnosis and treatment of cancer |
| 01/31/2002 | US20020012963 Nucleotide sequences coding preferential peptides; for use in diagnosing and treatment of allergies |
| 01/31/2002 | US20020012962 Nucleotide sequences coding fusion protein for use in the treatment of osteoporosis, cancers, and cachexia |
| 01/31/2002 | US20020012942 Polypeptides; for use in the diagnosis and treatment of cancer; antitumor agents; anticarcinogenic agents |